Table 4.

DXA parameters, stratified by MEN1-associated tumors.

Parameter	Total patients (n = 65)	Patients with PHPT (n = 53)	Patients without PHPT (n = 12)	Patients with GEP-NETs (n = 23)	Patients without GEP-NETs (n = 42)	Patients with functioning pituitary adenomas (n = 22)	Patients without functioning pituitary adenomas (n = 43)	Patients without the three main MEN1 tumors (n = 8)	Patients with only PHPT (n = 21)	Patients with only GEP-NET (n = 1)	Patients with only functioning pituitary adenoma (n = 2)	Patients with PHPT and GEP-NETs (n = 13)	Patients with PHPT and functioning pituitary adenomas (n = 11)	Patients with GEP-NETs and functioning pituitary adenomas (n = 1)	Patients with PHPT, GEP-NETs and functioning pituitary adenomas (n = 8)
Age at tumor diagnosis (years)	n.a.	36.1 ± 14.8	n.a.	40.3 ± 14.3	n.a.	28.2 ± 12.5	n.a.	n.a.	34.9 ± 15.8	38	30.0 ± 17.0	PHPT: 43.2 ± 12.4;GEP-NET: 42.5 ± 14.6	PHPT: 31.3 ± 13.2;Functioning pituitary adenoma: 25.4 ± 9.2	GEP-NET: 41; Functioning pituitary adenoma: 15	PHPT: 34.8 ± 16.1;GEP-NET: 36.6 ± 15.8;Functioning pituitary adenoma: 33.4 ± 15.4
Age at DXA measurement (years)	41.4 ± 16.3	42.9 ± 16.3	34.8 ± 15.3	45.2 ± 14.8	39.3 ± 16.9	39.2 ± 13.9	42.5 ± 17.4	31.3 ± 15.6	42.9 ± 18.4	43	42.0 ± 24.0	48.0 ± 15.3	37.9 ± 13.5	41	40.0 ± 15.0
Gap between tumor diagnosis and DXA measurement (years)	n.a.	6.7 ± 9.0	n.a.	3.6 ± 3.1	n.a.	11.0 ± 8.4	n.a.	n.a.	7.5 ± 11.8	5	12.0 ± 7.1	PHPT: 5.7 ± 7.0;GEP-NET: 6.3 ± 7.7	PHPT: 6.6 ± 5.9;Functioning pituitary adenoma: 12.5 ± 9.3	GEP-NET: 0; Functioning pituitary adenoma: 26	PHPT: 5.3 ± 4.2;GEP-NET: 3.4 ± 3.7;Functioning pituitary adenoma: 6.6 ± 4.8
Lumbar spine (L1–L4) BMD (g/cm2)	0.895 ± 0.146	0.891 ± 0.153	0.912 ± 0.117	0.897 ± 0.112	0.894 ± 0.162	0.887 ± 0.115	0.899 ± 0.161	0.911 ± 0.134	0.885 ± 0.190	0.893	0.948 ± 0.046	0.915 ± 0.139	0.886 ± 0.142	0.867	0.875 ± 0.084
Lumbar spine (L1–L4) T-score	−1.5 ± 1.4	−1.6 ± 1.4	−1.1 ± 1.0	−1.7 ± 0.9	−1.5 ± 1.6	−1.6 ± 1.2	−1.5 ± 1.5	−0.9 ± 1.2	−1.7 ± 1.8	−1.4	−1.1 ± 1.6	−1.6 ± 1.1	−1.5 ± 1.4	−1.6	−1.8 ± 0.9
Lumbar spine (L1–L4) Z-score	−1.0 ± 1.2	−1.1 ± 1.2	−0.8 ± 0.9	−1.1 ± 1.0	−1.0 ± 1.2	−1.3 ± 1.1	−0.9 ± 1.2	−0.7 ± 1.0	−1.0 ± 1.3	−1.1	−0.8 ± 1.1	−0.8 ± 1.1	−1.4 ± 1.4	−1.4	−1.5 ± 0.9
Femoral neck BMD (g/cm2)	0.704 ± 0.118	0.709 ± 0.117	0.682 ± 0.125	0.695 ± 0.116	0.708 ± 0.121	0.726 ± 0.104	0.692 ± 0.125	0.693 ± 0.150	0.700 ± 0.119	0.666	0.691 ± 0.078	0.679 ± 0.133	0.736 ± 0.118	0.595	0.584 ± 0.864
Femoral neck T-score	−1.6 ± 0.9	−1.6 ± 0.9	−1.7 ± 0.9	−1.7 ± 0.9	−1.6 ± 0.9	−1.3 ± 0.9	−1.8 ± 0.9	−1.6 ± 1.0	−1.7 ± 0.9	−1.6	−1.6 ± 0.9	−1.9 ± 0.9	−1.2 ± 0.9	−2.3	−1.3 ± 1.1
Femoral neck Z-score	−1.1 ± 0.8	−1.0 ± 0.8	−1.4 ± 0.8	−0.9 ± 0.9	−1.1 ± 0.8	−0.9 ± 0.8	−1.2 ± 0.8	−1.4 ± 1.0	−1.2 ± 0.6	−1.3	−1.1 ± 0.2	−1.0 ± 0.9	−0.8 ± 0.9	−2.0	−0.7 ± 0.8
Total femur BMD (g/cm2)	0.830 ± 0.167	0.842 ± 0.176	0.782 ± 0.123	0.844 ± 0.176	0.821 ± 0.163	0.857 ± 0.113	0.814 ± 0.191	0.781 ± 0.146	0.805 ± 0.201	0.758	0.833 ± 0.083	0.855 ± 0.222	0.876 ± 0.117	0.717	0.739 ± 0.092
Total femur T-score	−1.3 ± 1.0	−1.2 ± 1.0	−1.5 ± 0.8	−1.2 ± 0.9	−1.3 ± 1.0	−0.9 ± 0.9	−1.5 ± 0.9	−1.5 ± 0.9	−1.5 ± 1.0	−1.5	−1.1 ± 0.9	−1.3 ± 1.0	−0.8 ± 0.9	−1.8	−1.3 ± 1.1
Total femur Z-score	−0.9 ± 0.9	−0.8 ± 0.9	−1.2 ± 0.8	−0.8 ± 1.0	−1.0 ± 0.9	−0.7 ± 0.8	−1.0 ± 0.9	−1.2 ± 1.0	−1.1 ± 0.8	−1.3	−0.9 ± 0.6	−0.8 ± 1.2	−0.7 ± 0.9	−1.7	−0.5 ± 0.8
Normal BMD value (%)	14/65 (21.5)	11/53 (20.8)	3/12 (25.0)	3/23 (13.0)	11/42 (26.2)	7/22 (31.8)	7/43 (16.3)	2/8 (25.0)	3/21 (14.2)	0/1 (0)	1/2 (50.0)	2/13 (15.4)	5/11 (45.5)	0/1 (0)	1/8 (12.5)
Osteopenia (%)	30/65 (46.2)	23/53 (43.4)	7/12 (58.3)	12/23 (52.2)	18/42 (42.8)	11/22 (50.0)	19/43 (44.2)	4/8 (50.0)	9/21 (42.9)	1/1 (100)	1/2 (50.0)	5/13 (38.5)	4/11 (36.6)	1/1 (100)	5/8 (62.5)
Osteoporosis (%)	21/65 (32.3)	19/53 (35.8)	2/12 (16.7)	8/23 (34.8)	13/42 (31.0)	4/22 (18.2)	17/43 (39.5)	2/8 (25.0)	9/21 (42.9)	0/1 (0)	0/2 (0)	6/13 (46.1)	2/11 (18.2)	0/1 (0)	2/8 (25.0)

GEP-NETs, gastro-entero-pancreatic neuroendocrine tumors; n.a., not applicable; PHPT, primary hyperparathyroidism.